-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Philadelphia (Ph) chromosomes with t (9; 22)(q34; q11) subseign is characterized by the most common cytogenetic abnormality in patients with acute lymphoblastic leukemia (ALL).
about 25% of adult ALL patients with B-cell pregeners (BCP) have Ph chromosomal-positive (Ph-plus), characterized by the formation of the BCR-ABL1 fusion gene on Ph chromosomes.
Bonatumomab is a dual-specific CD19 CD3 T cell bridger that binds to CD19 on the surface of B cells and CD3 on the surface of T cells to connect T cells to malignant B cells to activate endogenetic T cells, thus acting as an anti-tumor. the
Study FlowChart ALCANTARA study is a multicenter, open-label Phase 2 one-arm trial that includes patients with relapses over the age of 18 or at least one TKI refractic Ph-ALL, with the aim of assessing the long-term durability of Bonathumab for use in such patients.
end point is to achieve full remission (CR)/full remission (CR) and partial hematological recovery (CRh) in the first two courses of Bona Tso monotherapy.
non-recurrence survival rate this analysis included 45 patients who completed the study between January 3, 2014 and January 6, 2017, 16 of whom (35.6%; 95% CI 21.9%-51.2%) obtained CR/CRh in the first two Bonatho monotherapy sessions.
16.1 months after the medium total survival rate, the medium recurrence period (RFS) was 6.8 months (95% CI 4.4 months - not reached.
25.1 months of medium follow-up, the total lifetime (OS) was 9.0 months (95% CI 5.7-13.5).
the remission duration of CR patients with MRD full responders was significantly longer than in non-CR patients (19.8 vs 6.0 months).
of the 16 patients who received CR/CRh, 14 received complete remission of micro-residual lesions (MRD), with a medium duration of 9.7 months (95% CI 5.2-NE).
treatment-related adverse events are consistent with previous reports.
, patients with R/R Ph-ALL had long-lasting responses to Bonatho monoantigen.
